SCHEMBL4872503

SCHEMBL4872503

O=C(O)N[C@@H](Cc1ccccc1)[C@H](O)CN(OC1CCCCC1)S(=O)(=O)c1ccc2c(c1)OCO2

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
LMNA P02545 2/20 0.41
MLNR O43193 1/20 0.41
ABCB11 O95342 1/20 0.41
CTSD P07339 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP3A5 P20815 1/20 0.41
CNR1 P21554 1/20 0.41
TBXAS1 P24557 1/20 0.41
ADRA1A P35348 1/20 0.41
TAS2R14 Q9NYV8 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
ABCB1 P08183 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4872512 1.00 ALDH1A1 (0.42) ALDH1A1LMNAMLNRABCB11CTSD
SCHEMBL7364021 0.99 ALDH1A1 (0.42) ALDH1A1LMNAMLNRABCB11CTSD
SCHEMBL4873623 0.96 ALDH1A1 (0.46) ALDH1A1LMNAMLNRABCB11CTSD
SCHEMBL4873631 0.96 ALDH1A1 (0.46) ALDH1A1LMNAMLNRABCB11CTSD
SCHEMBL4875283 0.89 KLK5 (0.43) LMNAMLNRABCB11CTSDCYP3A4
SCHEMBL4875275 0.89 KLK5 (0.43) LMNAMLNRABCB11CTSDCYP3A4
SCHEMBL4875377 0.85 CTSD (0.52) LMNAMLNRABCB11CTSDCYP3A4
SCHEMBL4872903 0.85 MLNR (0.44) LMNAMLNRABCB11CTSDCYP3A4
SCHEMBL7430780 0.85 MLNR (0.44) LMNAMLNRABCB11CTSDCYP3A4
SCHEMBL4872912 0.85 MLNR (0.44) LMNAMLNRABCB11CTSDCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7419967-B2 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-09-02 US claimed
US-20060172936-A1 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED 2006-08-03 US claimed
US-6613743-B2 Administering to a patient suffering from viral infections a sulfonamides antiviral agents which are aspartyl protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2003-09-02 US claimed
US-20020049201-A1 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED 2002-04-25 US claimed
US-7419967-B2 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-09-02 US disclosed
US-20060172936-A1 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED 2006-08-03 US disclosed
EP-1086076-B1 SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMA (US) 2004-12-22 EP disclosed
US-6613743-B2 Administering to a patient suffering from viral infections a sulfonamides antiviral agents which are aspartyl protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2003-09-02 US disclosed
US-20020049201-A1 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED 2002-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060172936-A1 Sulfonamide inhibitors of aspartyl protease SPINT2, PRSS1, DNPEP ALDH1A1 1841/4885LMNA 3901/4885MLNR 4045/4885
US-20020049201-A1 Sulfonamide inhibitors of aspartyl protease SPINT2, PRSS1, DNPEP ALDH1A1 1841/4885LMNA 3901/4885MLNR 4045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.